Capricor Reports Q3 2024 Results & Corporate Update
13 Nov 2024 //
GLOBENEWSWIRE
Capricor to Present Exosome Platform Updates at 2024 AEV Annual Meeting
12 Nov 2024 //
GLOBENEWSWIRE
Capricor Therapeutics to Present Q3 2024 Results on Nov 13
05 Nov 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Closes Underwritten Public Offering
18 Oct 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Prices $75 Million Public Offering of Stock
17 Oct 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Proposes Public Offering Of Common Stock
16 Oct 2024 //
GLOBENEWSWIRE
Capricor shares more data for DMD therapy after initiating BLA
11 Oct 2024 //
FIERCE BIOTECH
Capricor Announces Data from Study in DMD at Muscle Society Congress
11 Oct 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Initiates Rolling BLA For Deramiocel In DMD
09 Oct 2024 //
GLOBENEWSWIRE
Capricor To Present Long-Term Data From HOPE-2 Study At Congress
04 Oct 2024 //
GLOBENEWSWIRE
Capricor Therapeutics to File Application for Deramiocel Approval
24 Sep 2024 //
GLOBENEWSWIRE
Capricor To Provide Duchenne Muscular Dystrophy Update
23 Sep 2024 //
GLOBENEWSWIRE
Capricor sells Europe rights to DMD therapy for $35M FDA application approaches
19 Sep 2024 //
FIERCE BIOTECH
Capricor Signs Term Sheet With Nippon Shinyaku for Europe
17 Sep 2024 //
GLOBENEWSWIRE
Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
06 Sep 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Reports Q2 2024 Results And Corporate Update
07 Aug 2024 //
GLOBENEWSWIRE
Capricor Therapeutics To Report Q2 2024 Results On August 7
31 Jul 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
01 Jul 2024 //
GLOBENEWSWIRE
Capricor Reports Long-Term Benefits Of Deramiocel In Duchenne Muscular Dystrophy
28 Jun 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
25 Jun 2024 //
GLOBENEWSWIRE
CORRECTION: Capricor Therapeutics
25 Jun 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Announces +ve Type-B Meeting with FDA for CAP-1002 Program
11 Jun 2024 //
GLOBENEWSWIRE
Capricor: Positive 3-Year CAP-1002 Efficacy In Duchenne Muscular Dystrophy
04 Jun 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Q1 2024 Financials, Corporate Update
13 May 2024 //
GLOBENEWSWIRE
Capricor Exosome Platform Update At ASGCT Annual Meeting 2024
09 May 2024 //
GLOBENEWSWIRE
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
08 May 2024 //
GLOBENEWSWIRE
Capricor To Present Q1 2024 Results, Updates On May 13
06 May 2024 //
GLOBENEWSWIRE
Capricor`s Positive FDA Meeting for DMD Drug CAP-1002
24 Apr 2024 //
GLOBENEWSWIRE
Capricor Therapeutics to Present at Upcoming Investor Conferences
21 Mar 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Presents at 2024 MDA Clinical & Scientific Conference
06 Mar 2024 //
GLOBENEWSWIRE
Capricor Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA
27 Feb 2024 //
GLOBENEWSWIRE
Capricor to Present Fourth Quarter and Full Year 2023 Financial Results
22 Feb 2024 //
GLOBENEWSWIRE
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production
20 Feb 2024 //
GLOBENEWSWIRE
Capricor Announces Collaboration with the National Institutes of Health
24 Jan 2024 //
GLOBENEWSWIRE
Capricor Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002
11 Dec 2023 //
GLOBENEWSWIRE
Capricor Therapeutics Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Capricor Therapeutics to Present Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar
19 Oct 2023 //
GLOBENEWSWIRE
Capricor Therapeutics Announces Presentations at 28th Annual Congress
10 Oct 2023 //
GLOBENEWSWIRE
Capricor Announces Type-B Meeting to Discuss Pathway to BLA for CAP-1002
29 Sep 2023 //
GLOBENEWSWIRE
Capricor Therapeutics Announces $23 Million Registered Direct Offering
29 Sep 2023 //
GLOBENEWSWIRE
Capricor Therapeutics Appoints Michael Kelliher to Board of Directors
06 Sep 2023 //
GLOBENEWSWIRE
Capricor Therapeutics Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
PRESS RELEASE
Capricor Therapeutics to Present Second Quarter 2023 Financial Results
02 Aug 2023 //
GLOBENEWSWIRE
Capricor Announces Appointment of Philip J. Gotwals to its Board of Directors
24 Jul 2023 //
GLOBENEWSWIRE
Capricor Announces Appointment of Paul Auwaerter to its Board of Directors
13 Jul 2023 //
GLOBENEWSWIRE
Capricor Announces +ve 24-Month Results from Ongoing HOPE-2 Study of CAP-1002
30 Jun 2023 //
GLOBENEWSWIRE
Capricor to Present Results from HOPE-2 Extension Study of CAP-1002
13 Jun 2023 //
GLOBENEWSWIRE
Capricor Announces Follow-up Type-B Meeting with the FDA for CAP-1002
07 Jun 2023 //
GLOBENEWSWIRE
Capricor Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Capricor Therapeutics to Present 1Q 2023 FYR Recent Corporate Update on May 11
04 May 2023 //
GLOBENEWSWIRE
Capricor Announces Peer-Reviewed PublicationTherapeutic Potential of Exosome
27 Apr 2023 //
GLOBENEWSWIRE
Capricor Therapeutics Presents at 2023 (MDA) Clinical & Scientific Conference
23 Mar 2023 //
GLOBENEWSWIRE
Capricor Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
Capricor inks $100 M deal with Nippon Shinyaku for DMD treatment in Japan
20 Feb 2023 //
BIOSPECTRUM ASIA
Capricor and Nippon Shinyaku Enter Partnership Distribution of CAP-1002
16 Feb 2023 //
GLOBENEWSWIRE
Capricor Announces Results from HOPE-2 Open Label Extension Study of CAP-1002
25 Jan 2023 //
GLOBENEWSWIRE
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar
19 Jan 2023 //
GLOBENEWSWIRE
Capricor Announces Publication Highlighting Engineered Exosome Platform
12 Jan 2023 //
GLOBENEWSWIRE